Subclinical Atherosclerosis Is Associated with Discrepancies in BAFF and APRIL Levels and Altered Breg Potential of Precursor-like Marginal Zone B-Cells in Long-Term HIV Treated Individuals
Authors:
- Matheus ArangurenMAMatheus Aranguren
- Kim Doyon-LalibertéKDKim Doyon-Laliberté
- Mohamed El-FarMEMohamed El-Far
- Carl Chartrand-LefebvreCCCarl Chartrand-Lefebvre
- Jean-Pierre RoutyJRJean-Pierre Routy
- Jean-Guy BarrilJBJean-Guy Barril
- Benoît TrottierBTBenoît Trottier
- Cécile TremblayCTCécile Tremblay
- Madeleine DurandMDMadeleine Durand
- Johanne PoudrierJPJohanne Poudrier
- Michel RogerMRMichel Roger
Open Access
Abstract
Chronic inflammation persists in people living with HIV (PLHIV) despite antiretrovial therapy (ART) and is involved in their premature development of cardiovascular diseases (CVD) such as atherosclerosis. We have previously reported that an excess of “B-cell activating factor” (BAFF), an important molecule for the selection and activation of first-line Marginal Zone (MZ) B-cell populations, is associated with deregulations of precursor-like MZ (MZp), whose potent B-cell regulatory (Breg) capacities are altered in PLHIV, early on and despite 1–2 years of ART. Based on these observations, and growing evidence that MZ populations are involved in atherosclerosis control, we designed a cross sectional study to explore the associations between BAFF and its analogue “A proliferation-inducing ligand” (APRIL) with subclinical CVD in long-time-treated individuals of the Canadian HIV and Aging Cohort Study (CHACS) imaging sub-study group. We also characterized the Breg profile of MZp from the blood of these individuals. Results were correlated with the total volume of atherosclerotic plaques (TPV) and with CVD risk factors and biomarkers. TPV was measured using cardiac computerised tomography angiography, and presence of CVD was defined as TPV > 0. We report that blood levels of BAFF are elevated and correlate positively with CVD and its risk factors in PLHIV from the CHACS, in contrast to APRIL levels, which correlate negatively with these factors. The expression levels of Breg markers such as NR4A3, CD39, CD73 and CD83 are significantly lower in PLHIV when compared to those of HIV-uninfected controls. In vitro experiments show that APRIL upregulates the expression of Breg markers by blood MZp from HIV-uninfected individuals, while this modulation is dampened by the addition of recombinant BAFF. Altogether, our observations suggest that strategies viewed to modulate levels of BAFF and/or APRIL could eventually represent a potential treatment target for CVD in PLHIV.Keywords
All Related Versions
Funding Information
- Canadian Institutes of Health Research (PJT-148529, 284512, 398643, R01AG054324, 35381)
- Fonds de recherche du Québec en santé (FRQS) (PJT-148529, 284512, 398643, R01AG054324, 35381)
- National Institutes of Health (PJT-148529, 284512, 398643, R01AG054324, 35381)
- RBIQ-FRSQ 9e Concours 2013 project 9.04, Network SIDA-MI (FRQS) (PJT-148529, 284512, 398643, R01AG054324, 35381)
This publication has 62 references indexed in Scilit:
- Marginal zone B cells: virtues of innate-like antibody-producing lymphocytesNature Reviews Immunology, 2013
- Management of dyslipidemia in HIV-infected patientsClinical Lipidology, 2011
- Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general populationAIDS, 2010
- Cracking the BAFF codeNature Reviews Immunology, 2009
- B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammationExperimental & Molecular Medicine, 2009
- General Cardiovascular Risk Profile for Use in Primary CareCirculation, 2008
- Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2007
- Microbial translocation is a cause of systemic immune activation in chronic HIV infectionNature Medicine, 2006
- APRIL-Deficient Mice Have Normal Immune System DevelopmentMolecular and Cellular Biology, 2004
- The AIDS Disease of CD4C/HIV Transgenic Mice Shows Impaired Germinal Centers and Autoantibodies and Develops in the Absence of IFN-γ and IL-6Immunity, 2001